

Valentin Brodszky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312855/publications.pdf>

Version: 2024-02-01

105
papers

3,176
citations

218381

26
h-index

189595

50
g-index

125
all docs

125
docs citations

125
times ranked

3750
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis. <i>European Journal of Health Economics</i> , 2023, 24, 139-152.	1.4	6
2	Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 399-408.	0.7	13
3	Measurement properties of the ICECAP-A capability well-being instrument among dermatological patients. <i>Quality of Life Research</i> , 2022, 31, 903-915.	1.5	4
4	A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI- \leq 6* and Skindex-16*. <i>British Journal of Dermatology</i> , 2022, 186, 485-495.	1.4	16
5	Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 291-303.	1.0	1
6	In Search for Comparability: The PECUNIA Reference Unit Costs for Health and Social Care Services in Europe. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3500.	1.2	13
7	Assessment of health state utilities in dermatology: an experimental time trade-off value set for the dermatology life quality index. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	1.0	1
8	General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic. <i>Dermatitis</i> , 2022, 33, S92-S103.	0.8	5
9	Disease burden of patients with pemphigus from a societal perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 77-86.	0.7	9
10	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	1.5	6
11	Subjective expectations regarding longevity and future health: a cross-sectional survey among patients with Crohn's disease. <i>Colorectal Disease</i> , 2021, 23, 105-113.	0.7	2
12	The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. <i>Quality of Life Research</i> , 2021, 30, 1477-1490.	1.5	12
13	A Rasch model analysis of two interpretations of "not relevant" responses on the Dermatology Life Quality Index (DLQI). <i>Quality of Life Research</i> , 2021, 30, 2375-2386.	1.5	10
14	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters Levels, but Has No Effect on Body Composition Parameters. <i>Life</i> , 2021, 11, 535.	1.1	6
15	Narrow Vagina as a Predictor of Obstructive Voiding Dysfunction after Transobturator Sling Surgery. <i>Urologia Internationalis</i> , 2021, 105, 1092-1098.	0.6	2
16	Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review. <i>Value in Health</i> , 2021, 24, 1158-1171.	0.1	12
17	Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients. <i>Life</i> , 2021, 11, 919.	1.1	9
18	Musculoskeletal health and capability wellbeing: Associations between the HAQ-DI, ICECAP-A and ICECAP-O measures in a population survey. <i>Musculoskeletal Science and Practice</i> , 2021, 55, 102420.	0.6	1

#	ARTICLE	IF	CITATIONS
19	DLQIâ€R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. <i>British Journal of Dermatology</i> , 2020, 182, 1167-1175.	1.4	25
20	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	1.0	3
21	The relationship between IL-6 and thrombocytosis accompanying gastrointestinal tumours. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 215-219.	0.3	2
22	Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. <i>Value in Health</i> , 2020, 23, 1235-1245.	0.1	58
23	Productivity Loss in Patients With Chronic Diseases: A Pooled Economic Analysis of Hungarian Cost-of-Illness Studies. <i>Value in Health Regional Issues</i> , 2020, 22, 75-82.	0.5	3
24	Exploring the identification, validation, and categorization of costs and benefits of education in mental health: The PECUNIA project. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 325-331.	0.2	13
25	Exploring the identification, validation, and categorization of the cost and benefits of criminal justice in mental health: the PECUNIA project. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 418-425.	0.2	11
26	Capability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative data. <i>Quality of Life Research</i> , 2020, 29, 2863-2874.	1.5	13
27	Validity of EQâ€5Dâ€5L, Skindexâ€16, DLQI and DLQIâ€R in patients with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2584-2592.	1.3	25
28	Dermatology Life Quality Index (DLQI) score bands are applicable to DLQIâ€Relevant (DLQIâ€R) scoring. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e484-e486.	1.3	7
29	Did You Get What You Wanted? Patient Satisfaction and Congruence Between Preferred and Perceived Roles in Medical Decision Making in a Hungarian National Survey. <i>Value in Health Regional Issues</i> , 2020, 22, 61-67.	0.5	8
30	Exploring eHealth Literacy and Patient-Reported Experiences With Outpatient Care in the Hungarian General Adult Population: Cross-Sectional Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19013.	2.1	17
31	(Pharmaco)economic evaluations for mental health related services: the PECUNIA project. <i>European Journal of Public Health</i> , 2020, 30, .	0.1	6
32	Validity of the <sc>EQ</sc> â€5D in patients with pemphigus vulgaris and pemphigus foliaceus. <i>British Journal of Dermatology</i> , 2019, 180, 802-809.	1.4	27
33	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 537-549.	0.7	19
34	Patientâ€assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2106-2113.	1.3	7
35	Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS. <i>European Journal of Health Economics</i> , 2019, 20, 31-41.	1.4	6
36	Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?. <i>European Journal of Health Economics</i> , 2019, 20, 133-140.	1.4	18

#	ARTICLE	IF	CITATIONS
37	Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies. <i>European Journal of Health Economics</i> , 2019, 20, 141-154.	1.4	12
38	Validity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 43-55.	1.4	25
39	A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases. <i>European Journal of Health Economics</i> , 2019, 20, 119-132.	1.4	17
40	Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary. <i>European Journal of Health Economics</i> , 2019, 20, 17-30.	1.4	11
41	Patient and general population values for luminal and perianal fistulising Crohn's disease health states. <i>European Journal of Health Economics</i> , 2019, 20, 91-100.	1.4	5
42	Cost-of-illness studies in nine Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2019, 20, 155-172.	1.4	23
43	Subjective well-being in patients with pemphigus: a path analysis. <i>European Journal of Health Economics</i> , 2019, 20, 101-107.	1.4	7
44	EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review. <i>European Journal of Health Economics</i> , 2019, 20, 109-117.	1.4	8
45	Time to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e267-e269.	1.3	19
46	Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice. <i>Postępy Dermatologii i Alergologii</i> , 2019, 36, 589-594.	0.4	5
47	Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease. <i>Quality of Life Research</i> , 2019, 28, 141-152.	1.5	41
48	Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. <i>Advances in Therapy</i> , 2019, 36, 721-745.	1.3	7
49	Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations. <i>Current Medicinal Chemistry</i> , 2019, 26, 259-269.	1.2	34
50	Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. <i>United European Gastroenterology Journal</i> , 2018, 6, 310-321.	1.6	20
51	A detailed analysis of "not relevant" responses on the DLQI in psoriasis: potential biases in treatment decisions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 783-790.	1.3	40
52	Is the DLQI appropriate for medical decision-making in psoriasis patients?. <i>Archives of Dermatological Research</i> , 2018, 310, 47-55.	1.1	24
53	Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 1102-1108.	1.4	42
54	Association between quality of life and clinical characteristics in patients with morphea. <i>Quality of Life Research</i> , 2018, 27, 2525-2532.	1.5	21

#	ARTICLE	IF	CITATIONS
55	EQ-5D studies in cardiovascular diseases in eight Central and Eastern European countries: a systematic review of the literature. <i>Kardiologia Polska</i> , 2018, 76, 860-870.	0.3	19
56	Exploring the Relationship between Quality of Life (EQ-5D) and Clinical Measures in Adult Attention Deficit Hyperactivity Disorder (ADHD). <i>Applied Research in Quality of Life</i> , 2017, 12, 409-424.	1.4	4
57	Comparing self-perceived and estimated fracture risk by FRAX [®] of women with osteoporosis. <i>Archives of Osteoporosis</i> , 2017, 12, 4.	1.0	3
58	The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. <i>Advances in Therapy</i> , 2017, 34, 1128-1144.	1.3	64
59	Expression of G protein-coupled oestrogen receptor in melanoma and in pregnancy-associated melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1453-1461.	1.3	16
60	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	0.7	22
61	EQ-5D studies in musculoskeletal and connective tissue diseases in eight Central and Eastern European countries: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2017, 37, 1957-1977.	1.5	9
62	Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. <i>Quality of Life Research</i> , 2017, 26, 3409-3419.	1.5	51
63	Long-term costs and survival of prostate cancer: a population-based study. <i>International Urology and Nephrology</i> , 2017, 49, 1707-1714.	0.6	5
64	Bleeding out the quality-adjusted life years: evaluating the burden of primary dysmenorrhea using time trade-off and willingness-to-pay methods. <i>Pain</i> , 2017, 158, 2259-2267.	2.0	30
65	Access to biologicals in Crohn's disease in ten European countries. <i>World Journal of Gastroenterology</i> , 2017, 23, 6294.	1.4	35
66	Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 139-147.	0.7	15
67	Subjective health expectations of patients with age-related macular degeneration treated with anti-VEGF drugs. <i>BMC Geriatrics</i> , 2017, 17, 233.	1.1	17
68	A budget impact model for biosimilar infliximab in Crohn's disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 1-7.	0.7	44
69	Alopecia areata and health-related quality of life: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2016, 175, 561-571.	1.4	144
70	Valuation of pemphigus vulgaris and pemphigus foliaceus health states: a convenience sample experiment. <i>British Journal of Dermatology</i> , 2016, 175, 593-599.	1.4	15
71	Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 31-42.	1.4	50
72	Perceived Risks Contra Benefits of Using Biosimilar Drugs in Ulcerative Colitis: Discrete Choice Experiment among Gastroenterologists. <i>Value in Health Regional Issues</i> , 2016, 10, 85-90.	0.5	11

#	ARTICLE	IF	CITATIONS
73	EQ-5D in Central and Eastern Europe: 2000â€“2015. <i>Quality of Life Research</i> , 2016, 25, 2693-2710.	1.5	103
74	Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. <i>European Journal of Health Economics</i> , 2016, 17, 89-98.	1.4	41
75	Patientsâ€™ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 942-943.	0.5	21
76	Discrepancies between the Dermatology Life Quality Index and utility scores. <i>Quality of Life Research</i> , 2016, 25, 1687-1696.	1.5	16
77	Treatment preferences of originator versus biosimilar drugs in Crohnâ€™s disease; discrete choice experiment among gastroenterologists. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 22-27.	0.6	30
78	Social Utility Values for Pemphigus Vulgaris and Foliaceus: A Composite Time Trade-Off Study. <i>Value in Health</i> , 2015, 18, A673.	0.1	1
79	Use of biologics for psoriasis in Central and Eastern European countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2222-2230.	1.3	41
80	Cost of illness of medically treated benign prostatic hyperplasia in Hungary. <i>International Urology and Nephrology</i> , 2015, 47, 1241-1249.	0.6	11
81	Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis. <i>British Journal of Dermatology</i> , 2015, 173, 1076-1080.	1.4	24
82	Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. <i>Pathology and Oncology Research</i> , 2015, 21, 619-627.	0.9	17
83	Biosimilars for the management of rheumatoid arthritis: economic considerations. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 43-52.	1.3	83
84	Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1398-1405.	1.3	21
85	QUALITY OF LIFE OF PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN; RESULTS FROM A CROSS-SECTIONAL SURVEY IN GENERAL PRACTICES IN HUNGARY. <i>Ideggyogyaszati Szemle</i> , 2015, 68, 325-30.	0.4	2
86	Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. <i>Archives of Iranian Medicine</i> , 2015, 18, 153-9.	0.2	19
87	Quality of Life and Costs in Parkinson's Disease: A Cross Sectional Study in Hungary. <i>PLoS ONE</i> , 2014, 9, e107704.	1.1	31
88	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. <i>Health Expectations</i> , 2014, 17, 696-709.	1.1	24
89	Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists. <i>European Journal of Health Economics</i> , 2014, 15, 83-92.	1.4	20
90	Acceptability of less than perfect health states in rheumatoid arthritis: the patients' perspective. <i>European Journal of Health Economics</i> , 2014, 15, 73-82.	1.4	12

#	ARTICLE	IF	CITATIONS
91	Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 27-34.	1.4	14
92	Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. <i>European Journal of Health Economics</i> , 2014, 15, 53-64.	1.4	26
93	Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. <i>European Journal of Health Economics</i> , 2014, 15, 65-71.	1.4	108
94	Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres. <i>European Journal of Health Economics</i> , 2014, 15, 101-109.	1.4	22
95	Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. <i>European Journal of Health Economics</i> , 2014, 15, 111-119.	1.4	60
96	The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. <i>Human Reproduction</i> , 2012, 27, 1292-1299.	0.4	732
97	Health status and costs of ambulatory patients with multiple sclerosis in Hungary. <i>Ideggyogyaszati Szemle</i> , 2012, 65, 316-24.	0.4	7
98	Costs of dementia in Hungary. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 633-639.	1.5	30
99	Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. <i>Rheumatology</i> , 2010, 49, 1920-1928.	0.9	47
100	Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 303-309.	0.6	45
101	Adherence to biologic DMARD therapies in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1367-1378.	1.4	60
102	Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. <i>Medical Science Monitor</i> , 2010, 16, SR1-5.	0.5	7
103	Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. <i>Rheumatology International</i> , 2009, 30, 199-205.	1.5	36
104	Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 399-400.	0.6	11
105	Costs of rheumatoid arthritis in Hungary. <i>Journal of Rheumatology</i> , 2007, 34, 1437.	1.0	27